阿司匹林PEAR1、GP1BA基因表型与血栓弹力图吻合度研究  

Analysis ofcoincidence between PEAR1,GP1BA gene phenotype of aspirin and thrombologram

作　　者：钟德胜[1] 刘永健 王灿茂 梁伟丹 杨青锦 李楚云[1] ZHONG Desheng;LIU Yongjian;WANG Canmao;LIANG Weidan;YANG Qingjin;LI Chuyun(Department of Pharmacy,Hui Zhou Municipal Centre Hospital,Huizhou 516001,China)

机构地区：[1]惠州市中心人民医院,广东惠州516001 [2]南方科技大学医院,广东深圳518000 [3]广东医科大学药学院,广东东莞523000

出　　处：《现代医院》2023年第10期1631-1634,共4页Modern Hospitals

基　　金：广东省医学科学技术研究基金(A2023283);惠州市科学技术局课题(2022CZ010113)。

摘　　要：目的 探究惠州地区阿司匹林GP1BA(rs12041331)、PEAR1(rs6065)基因多态性分布情况及其与血栓弹力图结果的吻合情况。方法 选取2022年我院神经内科确诊为缺血性卒中且行阿司匹林GP1BA、PEAR1基因表型检测的患者612例,对其基因表型进行统计分析,初步得到惠州地区阿司匹林基因多态性分布情况;其中有112例患者同时进行了血栓弹力图检测,对AA抑制率结果进行统计,分析其与基因表型结果的吻合度是否一致。结果 惠州地区GP1BA基因的CC型基因频率非常高(91.99%),通过卡方检验,阿司匹林GP1BA、PEAR1的基因表型在不同性别无显著性差异(P>0.05),高应答占比仅33.01%;AA抑制率<50%占比13.39%,AA抑制率≥75%占比高达71.43%;亚组分析显示,基因表型为高应答组的AA抑制率最低,与中应答组、低应答组比均具有显著性差异(P<0.05)。结论 阿司匹林PEAR1、GP1BA基因检测可能不适用于惠州地区患者,因其并不能充分反映阿司匹林的抗血小板活性,需寻求更为相关的基因进行检测,以指导阿司匹林个体化治疗。Objective To investigate the polymorphism distribution of aspirin GP1BA(rs12041331) and PEAR1(rs6065) genes in Huizhou area and the coincidence with the results of thrombologram.Methods A total of 612 patients diagnosed with ischemic stroke and receiving aspirin GP1BA and PEAR1 genotyping were selected from neurology Department of our hospital in 2022.The genotyping was statistically analyzed,and the preliminary distribution of aspirin gene polymorphism in Huizhou was obtained.Among them,112 patients underwent thrombelastography test at the same time,and the results of AA inhibition rate were statistically analyzed to determine whether it was consistent with the results of genotyping.Results The CC gene frequency of GP1BA gene was very high(91.99%) in Huizhou area.Chi-square test showed that the gene phenotype of aspirin GP1BA and PEAR1 had no significant difference with sex(P0.05),and the proportion of high response was only 33.01%.AA inhibition rate 50% accounted for 13.39%,and AA inhibition rate ≥75% accounted for up to 71.43%.Subgroup analysis showed that the high-response group had the lowest AA inhibition rate,which was significantly different from the middle-response and low-response groups(P0.05).Conclusion PEAR1 and GP1BA gene testing of Aspirin may not be suitable for patients in Huizhou,because it cannot fully reflect the antiplatelet activity of aspirin.In order to guide the individualized treatment of aspirin,it is necessary to seek more relevant genes for detection.

关 键 词：阿司匹林 基因检测 血栓弹力图 个体化治疗 

分 类 号：R197[医药卫生—卫生事业管理]